MyFinsight
Home
Blog
About
Cash and cash
equivalents
$30,381K
(62.80%↑ Y/Y)
Accounts receivable
$27,778K
Other current assets
$3,926K
(-19.70%↓ Y/Y)
Restricted cash
$42K
(-61.82%↓ Y/Y)
Total, at cost
$14,647K
(2.44%↑ Y/Y)
Total current assets
$62,127K
(-51.44%↓ Y/Y)
Operating lease
right-of-use assets
$2,107K
(-48.09%↓ Y/Y)
Property and equipment,
net
$1,334K
(-35.34%↓ Y/Y)
Other assets
$759K
(18.59%↑ Y/Y)
Accumulated depreciation
$13,313K
(8.81%↑ Y/Y)
Total assets
$66,327K
(-50.76%↓ Y/Y)
Total liabilities and
stockholders' equity
$66,327K
(-50.76%↓ Y/Y)
Total liabilities
$34,443K
(4.88%↑ Y/Y)
Total stockholders'
equity
$31,884K
(-68.70%↓ Y/Y)
Accumulated deficit
-$666,745K
(-12.86%↓ Y/Y)
Total current
liabilities
$28,343K
(39.86%↑ Y/Y)
2023 common warrants
liability
$5,812K
(-36.76%↓ Y/Y)
Operating lease
liabilities, net of current...
$288K
(-91.04%↓ Y/Y)
Additional paid-in capital
$698,183K
(0.86%↑ Y/Y)
Accumulated other
comprehensive income
$437K
(4.05%↑ Y/Y)
Common stock, 0.0001
par value...
$9K
(0.00%↑ Y/Y)
Accrued liabilities
$18,696K
(53.13%↑ Y/Y)
Accounts payable
$6,431K
(63.35%↑ Y/Y)
Operating lease
liabilities, current
$3,152K
(-9.99%↓ Y/Y)
Finance lease
liabilities, current
$64K
(68.42%↑ Y/Y)
Back
Back
Balance Sheet
Aligos Therapeutics, Inc. (ALGS)
Aligos Therapeutics, Inc. (ALGS)
source: myfinsight.com